Tumor K17 expression has emerged as a defining biomarker of the most aggressive forms of PDAC, and it is currently being tested as a biomarker to predict chemotherapy response in this and other phase 2 clinical trials.9,10,11,12,13,30,31 Here, we report that K17 was associated with numerically decreased survival whether detected at diagnosis in FNA or in the postneoadjuvant setting using surgical specimens, although these exploratory observations were not statistically significant and require further validation. Here, KRT17 is linked to neoplasm.